Tag - Robert LeBoyer

Markets

Ladenburg starts Plus Therapeutics at buy; PT $8

Ladenburg Thalmann initiated coverage of Plus Therapeutics (NASDAQ:PSTV) with a “buy” rating and price target of $8. The stock closed at $2.43 on Jan. 22. The company’s lead product, rhenium nanoliposome (RNL), is a...

January 25, 2021

Markets

Roth starts coverage of 3 companies with novel approaches to AD

Roth Capital Partners initiated coverage of three companies – vtv Therapeutics (NASDAQ:VTVT), Anevex Life Sciences (NASDAQ:AVXL) and Neurotrope Biosciences (NASDAQ:NTRP) – that are developing drugs with novel...

March 9, 2018

Tag - Robert LeBoyer

Ladenburg starts Plus Therapeutics at buy; PT $8

Roth starts coverage of 3 companies with novel approaches to AD

General

More